BASEL (dpa-AFX) - Novartis (NVS) said that an investigational iptacopan or LNP023- an oral, targeted factor B inhibitor- met Phase II study primary endpoint in rare kidney disease IgA nephropathy
Phase II primary endpoint results for investigational iptacopan in IgAN demonstrated effective and clinically meaningful reduction of proteinuria1 – a key.
Novartis announces iptacopan met Phase II study primary endpoint in rare kidney disease IgA nephropathy (IgAN) streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Novartis Pharma AG: Novartis announces iptacopan met Phase II study primary endpoint in rare kidney disease IgA nephropathy (IgAN)
3-7
C3 glomerulopathy
Basel,
2
1 - Novartis today announced Phase II primary endpoint data showing investigational iptacopan (LNP023) - a first-in-class, oral, targeted factor B inhibitor - reduced protein in the urine (proteinuria), an increasingly recognized surrogate marker correlating with progression to kidney failure
2, and showed promise in stabilizing kidney function in patients with IgA nephropathy (IgAN)
1. The data were presented at the 58
th ERA-EDTA Congress held virtually from June 5-8, 2021.
In the Phase II study (NCT03373461), patients (n=112) with IgAN were randomized to placebo or different doses of iptacopan
Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis announces iptacopan met Phase II study primary endpoint in rare kidney disease IgA nephropathy (IgAN)